Статья
МЕСТО АГОМЕЛАТИНА В ТЕРАПИИ ТРЕВОЖНО-ДЕПРЕССИВНЫХ РАССТРОЙСТВ У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА
По данным Всемирной организации здравоохранения тревожно-депрессивные расстройства будут второй по значимости причиной инвалидности к 2020 г. Обзор посвящен современным представлениям о патофизиологии депрессии у больных ишемической болезнью сердца (ИБС) и возможностям антидепрессивной терапии. Дан анализ зарубежных и отечественных исследований, посвященных эффективности и безопасности применения агомелатина у больных, как с хронической ишемической болезнью сердца, так и у пациентов с нестабильной стенокардией и острым инфарктом миокарда. Рассмотрены различные точки зрения, свидетельствующие о необходимости дальнейших исследований для оценки краткосрочных и долгосрочных эффектов антидепрессантов у пациентов с ИБС в сочетании с тревожно-депрессивными расстройствами.
1. Kop W.J., Synowski S.J., Gottlieb S.S. Depression in heart failure: biobehavioral mechanisms. Heart Fail Clin. 2011;7(1):23-38.
2. Pizzi C., Santarella L., Manfrini O., et al. Ischemic heart disease and depression: an underestimated clinical association. G Ital Cardiol (Rome). 2013;14(7-8):526-37.
3. Hare D.L., Toukhsati S.R., Johansson P., Jaarsma T. Depression and cardiovascular disease: a clinical review. Eur Heart J. 2014;35(21):1365-72.
4. Saran R.K., Puri A., Agarwal M. Depression and the heart. Indian Heart J. 2012;64(4):397-401.
5. Garganeeva N.P., Petrova M.M., Evsjukov A.A., et al. The impact of depression on the course of coronary artery disease and quality of life of patients. Klinicheskaja Medicina. 2014;92(12):30-7. (In Russ.).
6. Chalmers J.A., Quintana D.S., Abbott M.J., Kemp A.H. Anxiety Disorders are Associated with Reduced Heart Rate Variability: A Meta-Analysis. Front Psychiatry. 2014;5:80.
7. Smith P.J., Blumenthal J.A. Psychiatric and behavioral aspects of cardiovascular disease: epidemiology, mechanisms, and treatment. Rev Esp Cardiol. 2011;64(10):924-33.
8. Celano C.M., Huffman J.C. Depression and cardiac disease: a review. Cardiol Rev. 2011;19(3):130-42.
9. Smulevich A.B. Depression in cardiovascular diseases. Psihicheskie Rasstrojstva v Obshhej Medicine. 2013;4:4-9. (In Russ.).
10. Ford D.E., Mead L.A., Chang P.P., et al. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med. 1998;158(13):1422-6.
11. Freedland K.E., Carney R.M., Rich M.W. Effect of depression on prognosis in heart failure. Heart Fail Clin. 2011;7(1):11-21.
12. Smeijers L., Mostofsky E., Tofler G.H., et al. Association between high levels of physical exertion, anger, and anxiety immediately before myocardial infarction with mortality during 10-year follow-up. J Am Coll Cardiol. 2015;66(9):1083-4.
13. Wrenn K.C., Mostofsky E., Tofler G.H., et al. Anxiety, anger, and mortality risk among survivors of myocardial infarction. Am J Med. 2013;126(12):1107-13.
14. Roest A.M., Zuidersma M., de Jonge P. Myocardial infarction and generalised anxiety disorder: 10year follow-up. Br J Psychiatry. 2012;200(4):324-9.
15. Huffman J.C. Review: depression after myocardial infarction is associated with increased risk of all-cause mortality and cardiovascular events. Evid Based Ment Health. 2013;16(4):110.
16. Carney R.M., Freedland K.E. Depression and heart rate variability in patients with coronary heart disease. Cleve Clin J Med. 2009;76(Suppl 2):S13-7.
17. Mazereeuw G., Herrmann N., Bennett S.A., et al. Platelet activating factors in depression and coronary artery disease: a potential biomarker related to inflammatory mechanisms and neurodegeneration. Neurosci Biobehav Rev. 2013;37(8):1611-21.
18. Sanner J.E., Frazier L. The role of serotonin in depression and clotting in the coronary artery disease population. J Cardiovasc Nurs. 2011;26(5):423-9.
19. Serrano C.V. Jr, Setani K.T., Sakamoto E., et al. Association between depression and development of coronary artery disease: pathophysiologic and diagnostic implications. Vasc Health Risk Manag. 2011;7:159-64.
20. Blumenthal J.A. New frontiers in cardiovascular behavioral medicine: comparative effectiveness of exercise and medication in treating depression. Cleve Clin J Med. 2011;78(Suppl 1):S35-S43.
21. Mavrides N., Nemeroff C. Treatment of depression in cardiovascular disease. Depress Anxiety. 2013;30(4):328-41.
22. Cohen H.W., Gibson G., Alderman M.H. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108:2-8.
23. Ha J.H., Wong C.K. Pharmacologic treatment of depression in patients with myocardial infarction. J Geriatr Cardiol. 2011;8(2):121-6.
24. Rejai S., Giardino N.D., Krishnan S., et al. Quality of life and baseline characteristics associated with depressive symptoms among patients with heart disease. Clin Epidemiol. 2012;4:181-6.
25. Lange-Asschenfeldt C., Lederbogen F. Antidepressant therapy in coronary artery disease. Nervenarzt. 2011;82(5):657-64.
26. Oh S.W., Kim J., Myung S.K., et al. Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies. Br J Clin Pharmacol. 2014;78(4):727-37.
27. Kimmel S.E., Schelleman H., Berlin J.A., et al. The effect of selective serotonin reuptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br J Clin Pharmacol. 2011;72(3):514-7.
28. Taylor C.B., Youngblood M.E., Catellier D., et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792-8.
29. Von Ruden A.E., Adson D.E., Kotlyar M. Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality. J Cardiovasc Pharmacol Ther. 2008;13(1):32-40.
30. Davidson K.W., Rieckmann N., Clemow L., et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010;170(7):600-8.
31. Elderon L., Whooley M.A. Depression and cardiovascular disease. Prog Cardiovasc Dis. 2013;55(6):511-23.
32. Kasper S., Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry. 2009;10(2):117-26.
33. Smeraldi E., Delmonte D. Agomelatine in depression. Expert Opin Drug Saf. 2013;12(6):873-80.
34. Manikandan S. Agomelatine: A novel melatonergic antidepressant. J Pharmacol Pharmacother. 2010;1(2):122-3.
35. Ushkalova A., Ushkalova E. Agomelatine (agomelatine) antidepressant with a novel mechanism of action. Vrach. 2011;5:41-4. (In Russ.).
36. Srinivasan V., De Berardis D., Shillcutt S.D., Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs. 2012;21(10):1503-22.
37. Green B. Focus on agomelatine. Curr Med Res Opin. 2011;27(4):745-9.
38. Stein D.J., Picarel-Blanchot F., Kennedy S.H. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol. 2013;28(2):151-9.
39. Pribytkov A.A., Panova N.B., Popova Ju.V., Emcov K.G. The efficacy of agomelatine in depressive disorders with anxiety. Zhurnal Nevrologii i Psihiatrii im. C.C. Korsakova. 2013;113(11-2):53-8. (In Russ.).
40. Gavrilova S.I., Kolyhalov I.V., Ponomareva E.V., Selezneva N.D. Experience of clinical application of agomelatine for the treatment of depression in elderly patients in outpatient practice. Zhurnal Nevrologii i Psihiatrii im. C.C. Korsakova. 2014;114(9):43-8. (In Russ.).
41. Lôo H., Daléry J., Macher J.P., Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin-agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. Encephale. 2003;29(2):165-71.
42. Singh S.P., Singh V., Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol. 2012;15(3):417-28.
43. Koesters M., Guaiana G., Cipriani A., et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. British Journal of Psychiatry. 2013;203:179-87.
44. Huang K.L., Lu W.C., Wang Y.Y., et al. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. Australian and New Zealand Journal of Psychiatry. 2014;48(7):663-71.
45. Taylor D., Sparshatt A., Varma S., Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g2496.
46. Srinivasan V., Zakaria R., Othman Z., et al. Agomelatine in depressive disorders: its novel mechanisms of action. Neuropsychiatry Clin Neurosci. 2012;24(3):290-308.
47. Orudzhev N.J., Poplavskaja O.V. Melatonergic antidepressant agomelatine (agomelatine) in the treatment of depressive disorders. Lekarstvennyj Vestnik. 2014;8(2):33-6. (In Russ.).
48. Laudon M., Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014;15(9):15924-50.
49. De Berardis D., Di Iorio G., Acciavatti T., et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets. 2011;10(1):119-32.
50. Racagni G., Riva M.A., Molteni R., et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry. 2011;12(8):574-87.
51. De Bodinat C., Guardiola-Lemaitre B., Mocaër E., et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9.(8):628-42.
52. Demyttenaere K. Agomelatine in treating generalized anxiety disorder. Expert Opin Investig Drugs. 2014;23(6):857-64.
53. Chutko L.S., Rozhkova A.V., Sidorenko V.A., et al. Generalized anxiety disorder: psychosomatic aspects and approaches to treatment. Zhurnal Nevrologii i Psihiatrii im. C.C. Korsakova. 2012;112(1):40-4. (In Russ.).
54. Abejuela H.R., Osser D.N. The psychopharmacology algorithm project at the Harvard south shore program: an algorithm for generalized anxiety disorder. Harv Rev Psychiatry. 2016;24(4):243-56.
55. Рoponina Т.М., Рoponina Yu.S., Gunderina K.I., Markov V.A. Status of mental status and the possibility of its correction in patients with acute coronary syndrome associated with anxiety and depressive disorders. Кompleksnye Problemy Serdechno-sosudistyh Zabolevanij. 2013;3:81-2. (In Russ.).
56. Gajfullina R., Kim Z., Strel'cova L., et al. Agomelatine in the complex treatment of patients with coronary artery disease. Vrach. 2012;9:78-82. (In Russ.).
57. Goodwin G.M., Boyer P., Emsley R., et al. Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. Int Clin Psychopharmacol. 2013;28(1):20-8.
58. Mihajlovicheva A.I., Janushko P.S. Applications of agomelatine in the treatment of anxiety and depressive disorders in patients with unstable angina. Bjulleten' Medicinskih Internet-konferencij. 2014;4(4):401-4. (In Russ.).
59. Smeraldi E., Delmonte D. Agomelatine in depression. Expert Opin Drug Saf. 2013;12(6):873-80.
60. Kirpichenko A.A. The newest antidepressant agomelatine in the treatment of affective spectrum disorders. Psihiatrija, Psihoterapija i Klinicheskaja Psihologija. 2014;2(16):87-91. (In Russ.).
61. Stacenko M.E., Shilina N.N., Turkina S.V. Efficacy of agomelatine in the recovery phase of myocardial infarction in patients with type 2 diabetes, and anxiety and depressive disorders. Psihiatrija i Psihofarmakoterapija. 2012;14(6):8-13. (In Russ.).
62. Medvedev V.E., Epifanov A.V. An innovative method of treatment of depression in patients with coronary heart disease. Obozrenie Psihiatrii i Medicinskoj Psihologii im. V.M. Behtereva. 2010;3:31-6. (In Russ.).
63. Heun R., Ahokas A., Boyer P., et al; Agomelatine Study Group. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry. 2013;74(6):587-94.